Peptide therapy has moved steadily from the edges of functional medicine into a more mainstream conversation about longevity, recovery, and healthy aging. With that increased attention comes an understandable question: Is it safe? The honest answer — the only medically responsible one — is that safety in peptide therapy is not a property of peptides in isolation. It is a function of the clinical context in which they are used.
At Ageless Future, a physician-led longevity medicine practice in Seattle, we believe that the safety profile of any peptide protocol is determined by three factors: the compound itself and what the current evidence shows, the thoroughness of patient screening before any protocol begins, and the ongoing oversight provided throughout treatment. This article addresses each of those factors directly.
The Evidence Base: What “Safety” Actually Means for Peptides
Before discussing clinical processes, it is worth grounding the conversation in what the research currently shows for some of the most commonly discussed therapeutic peptides.
BPC-157 has an extensive preclinical safety record across hundreds of published animal studies. Research has not documented organ toxicity, mutagenicity, or significant adverse effects at standard therapeutic doses in animal models. Its unusual structural stability — it retains its structure in human gastric juice for more than 24 hours — is part of what has made it a subject of sustained scientific interest. A 2025 review in PMC describes BPC-157 as activating multiple overlapping pathways involved in angiogenesis, fibroblast activity, and inflammation modulation. Importantly, while the preclinical record is encouraging, large-scale controlled human clinical trials have not yet been completed. The absence of a complete human trial record is not the same as evidence of harm — but it is an honest limitation that a responsible physician-led practice will acknowledge.
The regulatory environment around BPC-157 also warrants transparency. It is not FDA-approved for any human use. After being placed on the FDA’s restricted compounding list in 2023, it was removed from that list on April 15, 2026. The Pharmacy Compounding Advisory Committee is now scheduled to meet July 23–24, 2026 to consider whether to formally add BPC-157 to the 503A Bulks List — a decision that would determine whether licensed compounding pharmacies can prepare it under physician prescription going forward. This information is current as of publication; regulations in this space evolve and your provider will confirm what is currently available.
NAD+ precursors (NMN and NR) and IV NAD+ have a more established human safety record. A peer-reviewed scientific review found that NR and NMN are safe, well tolerated, and have been safely administered in human trials for up to 20–24 weeks. Researchers have confirmed that these compounds can measurably raise NAD+ levels in the bloodstream. IV NAD+ infusions have been described as “quite safe” in published small-cohort data, though they can produce uncomfortable temporary side effects during infusion — including abdominal cramping, nausea, and fatigue — that typically resolve after the session. As NPR’s May 2026 reporting noted, researchers believe the existing clinical trial data demonstrates “remarkable safety,” while also emphasizing that long-term risks remain unclear until larger, longer trials are completed.
Sermorelin, a synthetic GHRH analogue that stimulates the pituitary gland to produce its own growth hormone, was originally studied for pediatric use and has a known pharmacological profile. In adult wellness applications, it is used off-label under physician supervision. As with other peptides used in longevity medicine, it is not FDA-approved as an anti-aging treatment — its use in adult optimization contexts relies on physician clinical judgment and the existing evidence base. Because it stimulates endogenous growth hormone production rather than replacing GH directly, it preserves the body’s own feedback mechanisms — a feature that research suggests may offer a distinct safety profile compared to direct growth hormone replacement.
Before Any Protocol Begins: Comprehensive Screening
The most important safety measure in peptide therapy is what happens before a single compound is prescribed. A responsible physician-supervised program does not start with a catalog of peptides and work backward to a patient. It starts with the patient.
At Ageless Future, our intake process includes:
Full health history review. We evaluate your complete medical background — past diagnoses, current medications, surgical history, and any known contraindications. Certain conditions, including active cancer, some autoimmune disorders, and anticoagulant therapy, require careful assessment before any peptide protocol is considered.
Comprehensive baseline labs. Hormone panels, metabolic markers, inflammatory markers, and organ function tests give our physicians the data needed to understand where you are starting from. These labs also establish the baseline against which we measure your response over time.
A detailed goals conversation. Understanding what you are hoping to achieve — whether that’s improved recovery, better energy, enhanced cognitive clarity, or support for healthy aging — allows us to design a protocol appropriate to your biology and priorities. Generic protocols are not how precision medicine works.
Informed consent. You will receive a clear explanation of what is FDA-approved, what is used off-label, what the current evidence shows, and what remains uncertain. We do not oversell outcomes, and we do not present emerging science as settled fact.
During Treatment: What Ongoing Oversight Looks Like
Initiating a peptide protocol is not a single transaction. Physician supervision means active, ongoing monitoring throughout your program.
Follow-up lab work allows us to assess biomarker changes, confirm that your body is responding as expected, and identify any early signals that warrant adjusting the protocol. For Sermorelin, this includes monitoring IGF-1 levels. For NAD+ support, we track energy-related markers and patient-reported outcomes alongside objective data.
Regular clinical check-ins give your physician the opportunity to evaluate your subjective experience — how you’re feeling, what you’ve noticed, any side effects or unexpected responses — and adjust dosing or timing accordingly. Peptides are biologically active compounds, and individual responses vary. What works well for one patient may need fine-tuning for another.
Protocol adjustments. If you are not tolerating a compound well, or if your goals evolve, your protocol evolves with you. A static protocol with no mechanism for adjustment is not physician supervision — it is a prescription handed off and forgotten.
What to Look for in Any Peptide Therapy Provider
Whether you are evaluating Ageless Future or any other longevity clinic offering peptide therapy in Seattle or elsewhere, the following are non-negotiable markers of a responsible program:
- A licensed physician — not a wellness coach or “peptide specialist” without medical credentials — oversees your care. Endocrinology knowledge and an understanding of hormone physiology and drug interactions are essential.
- Baseline labs are required before treatment. Any provider who prescribes without labs is not practicing medicine responsibly.
- The regulatory status of each compound is disclosed. You should know what is FDA-approved, what is off-label, and what is pending regulatory review.
- Outcomes are presented honestly. Guarantees of specific results, dramatic before-and-after claims, and language like “reverse aging” are red flags — not credible medicine.
- Compounding pharmacy sourcing is transparent. Peptides should be sourced from licensed, accredited compounding pharmacies that operate under physician prescription.
The Ageless Future Approach
As a physician-led longevity practice in Seattle — and sister brand of Pinnacle Integrative Health — Ageless Future brings the standards of integrative and functional medicine to every peptide protocol we offer. We keep pace with the regulatory landscape (including ongoing FDA developments around BPC-157), stay current with the published evidence, and communicate honestly with our patients about what is known and what is still being studied.
Peptide therapy is not a guaranteed solution, and we will never present it as one. What it can be — for the right patient, in the right clinical context, with proper physician oversight — is a meaningful tool in a broader longevity strategy.
This content is for informational purposes only and does not replace personalized medical advice. Talk to your Ageless Future physician before starting any protocol.
Interested in learning whether peptide therapy is appropriate for you? Call us at (206) 624-0397 or fill out our contact form to schedule a consultation. We’ll review your labs, discuss your health history, and walk you through your options based on the current evidence — no pressure, no oversell.